Endovascular treatment of chronic mesenteric ischemia

Abstract

Insights

Endovascular treatment for chronic mesenteric ischemia (CMI) is safe and effective, though long-term patency rates for angioplasty and stenting require further investigation. This study reviews patient data and literature to assess outcomes.

Area of Science:

  • Vascular Surgery
  • Interventional Radiology
  • Gastroenterology

Background:

  • Data on endovascular treatment for chronic mesenteric ischemia (CMI) are limited.
  • Angioplasty for CMI often leads to early restenosis and requires repeat interventions.

Purpose of the Study:

  • To present patient data on endovascular CMI treatment.
  • To review current literature on endovascular CMI interventions.

Main Methods:

  • Retrospective review of 27 CMI patients treated between 2008-2012.
  • Analysis of data from 11 additional studies on endovascular CMI treatment.
  • Follow-up included ultrasonography, CT, and angiography.

Main Results:

  • Procedures were complication-free. 2-year patency rate was 50%.
  • Re-intervention was needed for restenosis in 5 patients; one required surgery for stent occlusion.
  • Literature review showed high 1-year patency rates (up to 80%) in recent studies, but lower rates after 3 years in earlier studies.

Conclusions:

  • Endovascular treatment of the superior mesenteric artery (SMA) is a safe and suitable option for CMI.
  • Long-term results and patency rates for endovascular CMI interventions remain a concern.